Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
TEV-53408 antibody treatment for nonsegmental vitiligo
Official title: A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo
Status: Closed to new participants
Description:
Teva Branded Pharmaceutical Products R&D LLC plans to enroll about 66 participants. The experimental antibody blocks IL-15, an immune signal that helps pigment-destroying T cells survive. Researchers hope it will reduce the immune attack on melanocytes and allow skin color to return. Possible risks include injection or infusion reactions, headache, and infections; longer-term risks are still being studied. People ages 18 to 75 may qualify. The study is underway but is no longer accepting new participants.
Start date: November 11, 2024
Completion date: January 31, 2029
Organizer: Teva Branded Pharmaceutical Products R&D LLC
Contact: Teva Medical Expert, MD
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- What is the best therapy for localized vitiligo?
Localized vitiligo, where the white patches are limited to one or a few areas of the body, can be managed with a few treatment approaches. The best therapy usually depends on th...
- Is it possible to stop the progression of vitiligo?
While it's not always possible to quickly stop vitiligo progression, there are some treatments that can help slow or halt the spread of the condition in many cases: Corticostero...
- What causes vitiligo?
The exact cause is a complex puzzle, but we know the foundation: It is pre-wired in your genes. Think of your genetics as a loaded spring, just waiting for a specific "trigger" ...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.